

MOL #55251

Inactivation and Biotransformation of the Endogenous Cannabinoids

Anandamide and 2-Arachidonoylglycerol

Marla L. Yates and Eric L. Barker[§]

Department of Medicinal Chemistry and Molecular Pharmacology, Purdue
University School of Pharmacy and Pharmaceutical Sciences, West Lafayette, IN

47907

MOL #55251

a) Running Title: AEA and 2-AG Inactivation

b) §To whom correspondence should be addressed: Eric L. Barker, Ph.D.,
Department of Medicinal Chemistry and Molecular Pharmacology, Purdue
University School of Pharmacy, 575 Stadium Mall Dr., West Lafayette, 47907-
2091. Tel.: 765-494-9940; Fax: 765-494-1414; E-mail: barkerel@purdue.edu

c) Number of text pages: 15

Number of tables: 0

Number of figures: 4

Number of references: 75

Number of words in Abstract: 160

Number of words in Introduction: n/a

Number of words in Discussion: n/a

d) List of nonstandard abbreviations used in the paper:

2-AG: 2-arachidonoylglycerol

AEA: anandamide

CB1: cannabinoid receptor 1

CB2: cannabinoid receptor 2

PPAR: peroxisome proliferator-activated receptor

FAAH: fatty acid amide hydrolase

MAGL: monoacylglycerol lipase

COX: cyclooxygenase

LOX: lipoxygenase

PG-EAs: prostaglandin-ethanolamides

PG-GEs: prostaglandin-glycerol esters

HETE-EA: hydroperoxyeicosatetraenoylethanolamide

HETE-GE: hydroperoxyeicosatetraenoic acid glycerol ester

SERI: selective endocannabinoid reuptake inhibitor

MOL #55251

Abstract

The cannabinoid field is currently an active research area. Anandamide (AEA) and 2-arachidonoylglycerol (2-AG) are the most characterized endogenous cannabinoids (also known as endocannabinoids). These neuromodulators have been implicated in various physiologically-relevant phenomena including mood (Witkin *et al.*, 2005), the immune response (Ashton, 2007), appetite (Kirkham and Tucci, 2006), reproduction (Wang *et al.*, 2006), spasticity (Pertwee, 2002), and pain (Hohmann and Suplita, 2006). Pharmacological manipulation of AEA and 2-AG signaling should prove to have significant therapeutic applications in disorders linked to endocannabinoid signaling. One way to alter endocannabinoid signaling is to regulate the events responsible for termination of the endocannabinoid signal – cellular uptake and metabolism. However, in order to pharmacologically exploit AEA and/or 2-AG signaling in this way, we must first gain a better understanding of the proteins and mechanisms governing these processes. This review serves as an introduction to the endocannabinoid system with an emphasis on the proteins and events responsible for the termination of AEA and 2-AG signaling.

Endocannabinoid Signaling

Anandamide (AEA) and 2-arachidonoylglycerol (2-AG) are the two most characterized members of the endocannabinoid family. AEA and 2-AG act as agonists for both intracellularly and extracellularly-localized receptors. Following on-demand biosynthesis, AEA and 2-AG serve as agonists for the G protein-

MOL #55251

coupled cannabinoid receptors CB1 and CB2 as well as the nuclear peroxisome proliferator-activated receptor (PPAR) family members PPAR α and PPAR γ (Felder *et al.*, 1993; Munro *et al.*, 1993; O'Sullivan, 2007). AEA is also an endogenous agonist for the vanilloid receptor channel TRPV1 (Zygmunt *et al.*, 1999; Smart *et al.*, 2000) and the GRP55 receptor (Pertwee, 2002; Ryberg *et al.*, 2007; Lauckner *et al.*, 2008). Cessation of AEA and 2-AG signaling occurs via a two-step process: 1) transport of endocannabinoids from the extracellular to the intracellular space, and 2) intracellular degradation by hydrolysis or oxidation.

Cellular Accumulation as a Mechanism for the Termination of Extracellular Endocannabinoid Signaling

Like typical neurotransmitters, endocannabinoids are translocated across the plasma membrane in order to cease their signaling at the extracellular cannabinoid receptors. However, the mechanism and proteins responsible for AEA and/or 2-AG transport remain elusive and hotly debated. While some researchers have proposed that these lipophilic endocannabinoids cross the cell plasma membrane via simple diffusion through the lipid bilayer (Glaser *et al.*, 2003; Glaser *et al.*, 2005; Kaczocha *et al.*, 2006), other data indicate that the uptake process is a protein-facilitated event (Hillard *et al.*, 1997; Hillard and Jarrahian, 2000; Rakhshan *et al.*, 2000; Beltramo and Piomelli, 2000). Numerous studies conducted in various cell types, both of neuronal and non-neuronal origin, have characterized AEA and 2-AG uptake as being temperature-dependent, saturable, and independent of energy in the form of ion gradients or adenosine

MOL #55251

triphosphate (ATP) hydrolysis (Rakhshan *et al.*, 2000;Maccarrone *et al.*, 2000;Hillard *et al.*, 1997;Hillard and Jarrahian, 2003;Hermann *et al.*, 2006;Deutsch *et al.*, 2001;Day *et al.*, 2001;Bisogno *et al.*, 2001;Beltramo and Piomelli, 2000). However, even among those in agreement with a protein-facilitated model for endocannabinoid uptake, there remains debate concerning the precise type of protein-facilitated event responsible.

Several different models have been proposed for endocannabinoid uptake that fit under the general heading of a protein-facilitated event: 1) transmembrane carrier (Hillard and Jarrahian, 2000;Beltramo *et al.*, 1997)), 2) intracellular sequestration (Hillard and Jarrahian, 2003;Hillard *et al.*, 2007), 3) passive diffusion driven by fatty acid amide hydrolase (FAAH) (Glaser *et al.*, 2003), and 4) carrier-mediated caveolae-related endocytosis (McFarland *et al.*, 2004;McFarland *et al.*, 2008;Rakhshan *et al.*, 2000). The majority of these models have been suggested as a result of experiments studying AEA transport only. Evidence exists though, which suggests that 2-AG and AEA are accumulated in cells via a common mechanism(s) (Beltramo and Piomelli, 2000). Both 2-AG and AEA uptake have been characterized as protein-facilitated events (Bisogno *et al.*, 2001;Beltramo and Piomelli, 2000). Additionally, 2-AG has been shown to inhibit AEA uptake in cells, indicating a competitive nature of the two endocannabinoids with regard to transport (Bisogno *et al.*, 2001;Beltramo and Piomelli, 2000).

Transmembrane Carrier Protein

MOL #55251

AEA diffusion across the lipid bilayer has been proposed to be facilitated by a membrane-localized protein carrier (Figure 1A) (Deutsch *et al.*, 2001; Hillard *et al.*, 1997; Hillard and Jarrahian, 2000; Ligresti *et al.*, 2004; Beltramo *et al.*, 1997). Much of the evidence for the existence of a membrane-localized endocannabinoid carrier protein stems from the observation that AEA transport in cells is bidirectional (Hillard *et al.*, 1997; Hillard and Jarrahian, 2000; Ligresti *et al.*, 2004; Maccarrone *et al.*, 2002). Studies conducted in both neuronal and non-neuronal cells demonstrate AEA efflux as well as uptake (Maccarrone *et al.*, 2002; Hillard *et al.*, 1997). In addition, experiments performed by Hillard and colleagues indicate that the elusive membrane-localized AEA carrier is capable of the trans-flux coupling effect, a phenomenon whereby in response to extracellular AEA, the membrane-localized carrier protein accumulates at the cell surface in the extracellular-facing direction (Hillard and Jarrahian, 2000).

Intracellular Sequestration Model

The intracellular sequestration of endocannabinoids by a fatty acid binding protein(s) is another proposed mechanism for endocannabinoid uptake suggested by Hillard and colleagues (Hillard and Jarrahian, 2003; Hillard *et al.*, 2007) (Figure 1B). Interestingly, this model simultaneously supports the proposition that AEA passively diffuses across the lipid bilayer and explains the characteristics of AEA uptake consistent with a protein-facilitated process. Following the unassisted translocation of AEA across the plasma membrane, the fatty acid-derived AEA may interact with fatty acid binding proteins (Hillard and Jarrahian, 2003). The intracellular sequestration of AEA by these binding

MOL #55251

proteins would remove AEA from the intracellular pool of “free” AEA, thus, promoting the inward concentration gradient and AEA uptake (Hillard and Jarrahian, 2003).

FAAH-Driven Passive Diffusion

FAAH-mediated hydrolysis of intracellular AEA does, to some extent, drive AEA uptake (Figure 1C). Our lab and others have shown that FAAH activity promotes AEA transport most likely by driving the concentration gradient along which AEA uptake occurs (Deutsch *et al.*, 2001; Day *et al.*, 2001; Cravatt *et al.*, 2001). Cells devoid of FAAH show diminished AEA accumulation as compared to those that basally express or over-express FAAH protein (Deutsch *et al.*, 2001; Day *et al.*, 2001). Additionally, recent evidence suggests that most “selective” AEA uptake inhibitors also inhibit FAAH activity (Dickason-Chesterfield *et al.*, 2006). This revelation subsequently begged the question as to whether or not a specific “AEA transport protein(s)” exists.

Intracellular enzymatic degradation is probably not solely responsible for the movement of endocannabinoids across the plasma membrane. The most compelling data arguing that FAAH alone is not responsible for endocannabinoid uptake comes from work with FAAH knockout mice where cells and tissues devoid of FAAH are still capable of accumulating AEA in a saturable and pharmacologically-manipulated manner (Ortega-Gutierrez *et al.*, 2004; Fegley *et al.*, 2004; Ligresti *et al.*, 2004). Similarly, Fowler and Ghafouri showed that 2-AG uptake is not prevented by pharmacological inhibition of 2-AG hydrolysis in all cell types, indicating possible cell-specific mechanisms for 2-AG uptake, but most

MOL #55251

importantly that hydrolysis is not the sole factor mediating transport (Fowler and Ghafouri, 2008).

Perhaps some of the most convincing evidence against FAAH being solely responsible for AEA uptake comes from the development of selective AEA uptake inhibitors. Ortar and colleagues announced their development of a series of tetrazole-based selective anandamide uptake inhibitors that do not inhibit FAAH or other metabolizing enzymes, thus, supporting the existence of a distinct protein target responsible for mediating endocannabinoid uptake (Ortar *et al.*, 2008). All of these data taken together suggest that, in addition to FAAH activity, a distinct protein-facilitated transport process is responsible for promoting the cellular accumulation of AEA.

Carrier-Mediated Caveolae-Related Endocytosis

Our lab has proposed that AEA uptake occurs via a protein carrier-mediated caveolae-related endocytic event (Figure 1D) (Rakhshan *et al.*, 2000;McFarland *et al.*, 2004;McFarland *et al.*, 2008). We demonstrated that inhibition of caveolae-related endocytosis or prevention of caveolae formation both led to a significant decrease in cellular AEA accumulation, thus, implicating a role for these membrane microdomains in the AEA uptake process (McFarland *et al.*, 2004;McFarland *et al.*, 2008). We propose that extracellular AEA binds a carrier protein located within caveolae, and that subsequently, caveolae-derived vesicle formation and endocytosis of the membrane-packaged endocannabinoid is induced (McFarland *et al.*, 2004;McFarland *et al.*, 2008;McFarland and Barker, 2004). The subsequent delivery of internalized AEA to FAAH may be a critical

MOL #55251

step in freeing up the carrier protein for additional AEA transport events. As described, carrier-mediated endocytosis could be used to reconcile most of the other models for endocannabinoid uptake discussed above, including: the FAAH-mediated maintenance of the AEA concentration gradient; the existence of a membrane-localized AEA binding protein; and the possible sequestration of intracellular AEA.

Catabolic Degradation as a Mechanism for Terminating Endocannabinoid

Signaling

Following cellular uptake, AEA and 2-AG are subject to metabolism by the serine hydrolases fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), respectively. Additionally, AEA and 2-AG have been shown to undergo oxidation by cyclo-oxygenase-2 (COX-2) and the 12- and 15-lipoxygenases (12-LOX and 15-LOX) (Di Marzo, 2006).

Catalytic degradation/modification of AEA and 2-AG not only serves as a mechanism for the augmentation of cellular uptake and cessation of extracellular signaling as mentioned above, but also regulates the intracellular signaling events of these two endocannabinoids. Below, we will briefly review the roles of the aforementioned enzymes in AEA and 2-AG metabolism.

Endocannabinoid Hydrolysis: FAAH1, FAAH2, and MAGL

FAAH1 and FAAH2 FAAH-mediated hydrolysis of AEA yields arachidonic acid and ethanolamine (Figure 2A) (Deutsch and Chin, 1993). Currently, two FAAH isoforms (FAAH1 and FAAH2) have been identified (Cravatt *et al.*, 1996; Wei *et*

MOL #55251

al., 2006). The intracellularly-localized FAAH1 and FAAH2 are both members of the amidase signature protein family and share approximately 20 percent sequence identity (McKinney and Cravatt, 2005; Wei *et al.*, 2006; Giang and Cravatt, 1997; McFarland *et al.*, 2004). Both isoforms are integral membrane proteins, owing to a single transmembrane domain on their respective N-termini, although their orientation in the membrane differs (Cravatt *et al.*, 1996; Wei *et al.*, 2006). FAAH1 has been proposed to contain a cytoplasmic-facing C-terminus, whereas the C-terminus of FAAH2 faces the lumen (Wei *et al.*, 2006). The two FAAH isoforms also vary in their expression patterns (Wei *et al.*, 2006). FAAH1 has been cloned from several different species, including mice, rats, and humans and is preferentially expressed in the brain, testis, and small intestine (McKinney and Cravatt, 2005; Wei *et al.*, 2006). FAAH2 is not expressed in rodents and is the predominant isoform found in cardiac tissue (Wei *et al.*, 2006). Also, FAAH1 has been reported to have greater activity with regard to fatty acid ethanolamides such as AEA (Wei *et al.*, 2006).

MAGL Although some reports suggest that FAAH may also play a role in 2-AG degradation (Di Marzo, 2006), the major enzyme responsible for 2-AG metabolism appears to be the serine hydrolase MAGL (Dinh *et al.*, 2002). MAGL has no sequence similarity with any member of the amidase signature protein family, including either FAAH isoform, or any other mammalian protein (Saario and Laitinen, 2007). However, MAGL does contain the α/β -hydrolase fold common to many lipases (Saario and Laitinen, 2007). As a proposed serine hydrolase, MAGL is capable of hydrolyzing both medium- and long-chain fatty

MOL #55251

acids (Saario and Laitinen, 2007). MAGL-mediated hydrolysis of 2-AG yields arachidonic acid and glycerol (Figure 2B) (Karlsson *et al.*, 1997).

Overexpression and siRNA-mediated knockdown of MAGL results in increased and decreased 2-AG inactivation, respectively (Dinh *et al.*, 2004;Dinh *et al.*, 2002). MAGL protein is expressed in a variety of human, rat, and mouse tissues (Saario and Laitinen, 2007;Long *et al.*, 2009).

Endocannabinoid Oxidation: COX-2 and the 12- and 15-Lipoxygenases

AEA and 2-AG are not only subject to hydrolysis, but because of their structure can also be metabolized by several of the same enzymes that are responsible for arachidonic acid oxidation, including COX-2 and the 12- and 15-lipoxygenases (Di Marzo, 2006).

COX-2 COX-2 is responsible for catalyzing the oxidation of AEA and 2-AG into various prostaglandin-ethanolamides (PG-EAs or prostamides) and prostaglandin-glycerol esters (PG-GEs), respectively (Figure 3A and B) (Woodward *et al.*, 2008). Until recently, whether or not such metabolites existed *in vivo* was unknown. However, Hu and colleagues have provided evidence to suggest that, indeed, at least some such *in vivo* reactions do occur (Shu-Jung Hu *et al.*, 2008). Interestingly, the endocannabinoid-derived prostaglandins have unique pharmacological profiles that appear to involve as-of-yet unidentified receptors (Shu-Jung Hu *et al.*, 2008;Woodward *et al.*, 2008;Di Marzo, 2006).

Lipoxygenases AEA and 2-AG have also been identified as substrates for both 12-LOX and 15-LOX in intact cells . Oxidative metabolism of AEA by 12-LOX and 15-LOX results in the formation of 12- and 15-

MOL #55251

hydroperoxyeicosatetraenoylethanolamide (12-HETE-EA and 15-HETE-EA), respectively (Figure 4A) (Edgemond *et al.*, 1998;Veldhuis *et al.*, 2003). Likewise, 12-LOX- and 15-LOX-mediated oxidation of 2-AG results in the formation of 12- and 15-hydroperoxyeicosatetraenoic acid glycerol ester (12-HETE-GE and 15-HETE-GE), respectively (Figure 4B) (Kozak *et al.*, 2002;Moody *et al.*, 2001). Unlike the endocannabinoid-derived prostaglandins, the lipoxygenase derivatives of AEA and 2-AG appear to mediate their biological activities via established receptors, including the cannabinoid receptors, PPAR- α , and TRPV1 (Di Marzo, 2006;Edgemond *et al.*, 1998;Kozak *et al.*, 2002;Craib *et al.*, 2001).

Pharmacological Manipulation of Endocannabinoid Uptake and Metabolism

The cannabinoid system is currently an active research area due to the many physiological and pathophysiological implications associated with AEA and 2-AG signaling such as appetite (Kirkham and Tucci, 2006), pain (Hohmann and Suplita, 2006), anxiety (Witkin *et al.*, 2005), fertility (Wang *et al.*, 2006), neurodegeneration (Battista *et al.*, 2006), the immune response (Ashton, 2007), and cardiac health (Ashton and Smith, 2007). Pharmacological manipulation of endogenous AEA and 2-AG levels is one way to selectively regulate their associated signaling events for therapeutic purposes. Thus, the proteins involved in endocannabinoid uptake and metabolism, the events responsible for termination of endocannabinoid signaling, are attractive targets for pharmacological exploitation aimed at modulating AEA and 2-AG signaling.

The Search for Selective Endocannabinoid Reuptake Inhibitors (SERIs)

MOL #55251

Unfortunately, the combination of the elusiveness of the protein(s) responsible for AEA and/or 2-AG uptake along with the unresolved relationship that exists between endocannabinoid uptake and FAAH/MAGL activity has hindered the development of SERIs. In fact, one 2006 study showed that nearly all “selective” AEA uptake inhibitors also block FAAH activity to one extent or another (Dickason-Chesterfield *et al.*, 2006).

Yet, recent developments indicate that the identities of the endocannabinoid transporter(s) may soon be determined. Moore and colleagues announced their development of the potent tetrazole-based specific AEA uptake inhibitor LY2318912 (Moore *et al.*, 2005). This compound appears to bind a protein target distinct from FAAH and does not cross the cell membrane, supporting the hypothesis of a plasma membrane localized or associated AEA carrier (Moore *et al.*, 2005). Additionally, several new molecules designed to isolate and identify the putative transporter protein(s) have recently been developed, including several photo-affinity radioligands as well as a biotin-tagged AEA (Balas *et al.*, 2005; Balas *et al.*, 2006; Fezza *et al.*, 2008; Moore *et al.*, 2005; Moriello *et al.*, 2006).

The increased specificity for endocannabinoid uptake inhibition exhibited by some of the tetrazole-based compounds may prove to be useful not only in the identification of the elusive protein(s) involved in endocannabinoid transport, but also in dissecting the role of endocannabinoid signaling in certain physiological and behavioral phenomena. Trezza and Vanderschuren suggest that the results of *in vivo* studies utilizing endocannabinoid reuptake inhibitors

MOL #55251

may be affected by the specificity of the inhibitor used (Trezza and Vanderschuren, 2009). They found that the non-specific uptake inhibitor AM404 and the more-specific uptake inhibitor VDM11 had contradicting effects on the social play of rats possibly due to off-target effects elicited by AM404 that are unassociated with CB1, CB2, or TRPV1 receptors (Trezza and Vanderschuren, 2009). Thus, compounds that specifically inhibit endocannabinoid uptake will better elucidate the true behavioral and physiological consequences of augmented endocannabinoid signaling.

Although many compounds initially thought to be specific for the endocannabinoid transporter have been shown to also inhibit FAAH and/or MAGL, these non-specific AEA uptake inhibitors do have utility in endocannabinoid research. For instance, *in vivo* studies using AM404 have implicated the endocannabinoid system in the neuropathic and inflammatory pain pathways (La Rana *et al.*, 2008; Mitchell *et al.*, 2007) as well as in the mediation of antidepressant-like effects (Adamczyk *et al.*, 2008). AM404 has also been shown to reduce ethanol administration in rats, suggesting utility for the compound in the treatment of alcoholism, although the exact signaling pathway responsible for this effect is unknown (Cippitelli *et al.*, 2007).

Inhibitors of AEA and 2-AG Hydrolysis

In instances where increased AEA or 2-AG signaling may have therapeutic benefit such as chronic pain or anxiety, inhibition of AEA and 2-AG enzyme-mediated hydrolysis may be desirable. Specifically inhibiting FAAH could increase AEA signaling in two ways: 1) by preventing AEA hydrolysis and,

MOL #55251

2) by decreasing the rate of AEA uptake into cells by interfering with the inward concentration gradient perpetuated by intracellular AEA hydrolysis.

In addition, the metabolites of AEA and 2-AG hydrolysis may themselves play roles in disease. For instance, 2-AG metabolites have been implicated as stimulatory factors in the pathogenesis of prostate cancer (Endsley *et al.*, 2007). Endsley and colleagues observed that in the androgen-independent prostate carcinoma (PC-3) cells, exogenous application of 2-AG increased production of arachidonic acid, which is then oxidized by 12-lipoxygenase. The resulting oxidized product, 12-HETE-GE, stimulates prostate cell invasion (Endsley *et al.*, 2007). The authors propose that inhibition of 2-AG hydrolysis in such instances may prove to have therapeutic potential (Endsley *et al.*, 2007).

Over the years, a significant number of FAAH inhibitors have been developed (for a review, see Seierstad and Breitenbucher, 2008). In addition to the development of FAAH inhibitors, some compounds currently on the market, including several NSAIDS, have been shown to inhibit FAAH activity (Fowler *et al.*, 2001; Seierstad and Breitenbucher, 2008). However, the development of MAGL inhibitors has lagged historically. Evidence suggests that boronic acids potently inhibit FAAH and may serve as good starting compounds for the development of better MAGL inhibitors (Minkkila *et al.*, 2008). Recently, Long and colleagues announced their development of a selective MAGL inhibitor JZL184 that produces antinociceptive effects, hypomotility, and hypothermia in mice (Long *et al.*, 2009). This advancement offers many possibilities not only for therapeutic development of MAGL inhibitors, but also with regard to research

MOL #55251

aimed at dissecting the overlapping and distinct effects of AEA and 2-AG signaling.

Endocannabinoid-derived Oxidative Metabolites as Pharmacological Targets

There have been many pathophysiological implications for the endocannabinoid-derived oxidative metabolites produced by COX-2 and the 12- and 15-LOXs. For example, data exist suggesting that COX-2-mediated oxidation of endocannabinoids plays an important regulatory role in hippocampal neuronal transmission and synaptic plasticity (Yang *et al.*, 2008; Sang *et al.*, 2006). Additionally, as briefly mentioned earlier, 12-LOX-generated oxidative metabolites of AEA may be agonists for TRPV1, a key channel in pain modulation (Craib *et al.*, 2001). These are just two examples of cell signaling events potentially mediated by the oxidative metabolites of AEA and 2-AG. Many questions still remain regarding the signaling fates of these and other endocannabinoid metabolites.

This mini-review has examined the various ways in which the endocannabinoids AEA and 2-AG may be inactivated. Endocannabinoid inactivation can be pharmacologically modulated at the level of cellular accumulation or intracellular metabolism. Metabolism occurs predominantly via the hydrolytic enzymes FAAH and MAGL or the oxidative enzymes COX-2, 12-LOX, and 15-LOX. The molecular process responsible for the intracellular accumulation of AEA and 2-AG has yet to be fully elucidated, but the majority of data to date suggest that endocannabinoid uptake is protein-facilitated. Much still remains to be learned regarding these events, including the identity of the

MOL #55251

putative endocannabinoid transporter(s) as well as identification of the signaling events mediated by the metabolic derivatives of AEA and 2-AG.

Acknowledgments

We thank Mr. David Allen for assistance in preparing Figure 1.

MOL #55251

References

- Adamczyk P, Golda A, McCreary A C, Filip M and Przegalinski E (2008) Activation of Endocannabinoid transmission induces antidepressant-like effects in rats. *J Physiol Pharmacol* **59**: 217-228.
- Ashton JC (2007) Cannabinoids for the treatment of inflammation. *Curr Opin Investig Drugs* **8**: 373-384.
- Ashton JC and Smith P F (2007) Cannabinoids and cardiovascular disease: the outlook for clinical treatments. *Curr Vasc Pharmacol* **5**: 175-185.
- Balas L, Cascio M G, Di Marzo V and Durand T (2006) Synthesis of a potential photoactivatable anandamide analog. *Bioorg Med Chem Lett* **16**: 3765-3768.
- Balas L, Hellal M, Rossi J C and Durand T (2005) Synthesis of a photoactivatable probe of the anandamide re-uptake. *Nat Prod Res* **19**: 419-423.
- Battista N, Fezza F, Finazzi-Agro A and Maccarrone M (2006) The endocannabinoid system in neurodegeneration. *Ital J Biochem* **55**: 283-289.
- Beltramo M and Piomelli D (2000) Carrier-mediated transport and enzymatic hydrolysis of the endogenous cannabinoid 2-arachidonylglycerol. *Neuroreport* **11**: 1231-1235.
- Beltramo M, Stella N, Calignano A, Lin S Y, Makriyannis A and Piomelli D (1997) Functional role of high-affinity anandamide transport, as revealed by selective inhibition. *Science* **277**: 1094-1097.
- Bisogno T, Maccarrone M, De Petrocellis L, Jarrahian A, Finazzi-Agro A, Hillard C and Di M, V (2001) The uptake by cells of 2-arachidonoylglycerol, an endogenous agonist of cannabinoid receptors. *Eur J Biochem* **268**: 1982-1989.
- Cippitelli A, Bilbao A, Gorriti M A, Navarro M, Massi M, Piomelli D, Ciccocioppo R and Rodriguez d F (2007) The anandamide transport inhibitor AM404 reduces ethanol self-administration. *Eur J Neurosci* **26**: 476-486.
- Craib SJ, Ellington H C, Pertwee R G and Ross R A (2001) A possible role of lipoxygenase in the activation of vanilloid receptors by anandamide in the guinea-pig bronchus. *Br J Pharmacol* **134**: 30-37.
- Cravatt BF, Giang D K, Mayfield S P, Boger D L, Lerner R A and Gilula N B (1996) Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. *Nature* **384**: 83-87.
- Cravatt BF, Demarest K, Patricelli M P, Bracey M H, Giang D K, Martin B R and Lichtman A H (2001) Supersensitivity to anandamide and enhanced endogenous

MOL #55251

cannabinoid signaling in mice lacking fatty acid amide hydrolase. *Proc Natl Acad Sci U S A* **98**: 9371-9376.

Day TA, Rakhshan F, Deutsch D G and Barker E L (2001) Role of fatty acid amide hydrolase in the transport of the endogenous cannabinoid anandamide. *Mol Pharmacol* **59**: 1369-1375.

Deutsch DG and Chin S A (1993) Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. *Biochem Pharmacol* **46**: 791-796.

Deutsch DG, Glaser S T, Howell J M, Kunz J S, Puffenbarger R A, Hillard C J and Anbumrad N (2001) The cellular uptake of anandamide is coupled to its breakdown by fatty-acid amide hydrolase. *J Biol Chem* **276**: 6967-6973.

Di Marzo V (2006) Endocannabinoids: synthesis and degradation, in *Reviews of Physiology Biochemistry and Pharmacology* (Amara SG, Bamberg E, Fleischmann BK, Gudermann Th, Hebert SC, Jahn R, Lederer WJ, Lill R, Miyajima A, Offermanns S, Zechner R eds) pp 1-24, Springer, Berlin/Heidelberg.

Dickason-Chesterfield A, Kidd S, Moore S, Schaus J, Liu B, Nomikos G and Felder C (2006) Pharmacological characterization of endocannabinoid transport and fatty acid amide hydrolase inhibitors. *Cell Mol Neurobiol* **26**: 407-423.

Dinh TP, Freund T F and Piomelli D (2002) A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation. *Chem Phys Lipids* **121**: 149-158.

Dinh TP, Kathuria S and Piomelli D (2004) RNA interference suggests a primary role for monoacylglycerol lipase in the degradation of the endocannabinoid 2-arachidonoylglycerol. *Mol Pharmacol* **66**: 1260-1264.

Edgmond WS, Hillard C J, Falck J R, Kearn C S and Campbell W B (1998) Human platelets and polymorphonuclear leukocytes synthesize oxygenated derivatives of arachidonylethanolamide (anandamide): their affinities for cannabinoid receptors and pathways of inactivation. *Mol Pharmacol* **54**: 180-188.

Endsley MP, Aggarwal N, Isbell M A, Wheelock C E, Hammock B D, Falck J R, Campbell W B and Nithipatikom K (2007) Diverse roles of 2-arachidonoylglycerol in invasion of prostate carcinoma cells: location, hydrolysis and 12-lipoxygenase metabolism. *Int J Cancer* **121**: 984-991.

Fegley D, Kathuria S, Mercier R, Li C, Goutopoulos A, Makriyannis A and Piomelli D (2004) Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172. *Proc Natl Acad Sci U S A* **101**: 8756-8761.

Felder CC, Briley E M, Axelrod J, Simpson J T, Mackie K and Devane W A (1993) Anandamide, an endogenous cannabimimetic eicosanoid, binds to the

MOL #55251

cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. *Proc Natl Acad Sci U S A* **90**: 7656-7660.

Fezza F, Oddi S, Di Tommaso M, De Simone C, Rapino C, Pasquariello N, Dainese E, Finazzi-Agro A and Maccarrone M (2008) Characterization of biotin-anandamide, a novel tool for the visualization of anandamide accumulation. *J Lipid Res* **49**: 1216-1223.

Fowler CJ and Ghafouri N (2008) Does the hydrolysis of 2-arachidonoylglycerol regulate its cellular uptake? *Pharmacol Res* **58**: 72-76.

Fowler CJ, Jonsson K O and Tiger G (2001) Fatty acid amide hydrolase: biochemistry, pharmacology, and therapeutic possibilities for an enzyme hydrolyzing anandamide, 2-arachidonoylglycerol, palmitoylethanolamide, and oleamide. *Biochem Pharmacol* **62**: 517-526.

Giang DK and Cravatt B F (1997) Molecular characterization of human and mouse fatty acid amide hydrolases. *Proc Natl Acad Sci U S A* **94**: 2238-2242.

Glaser ST, Abumrad N A, Fatade F, Kaczocha M, Studholme K M and Deutsch D G (2003) Evidence against the presence of an anandamide transporter. *Proc Natl Acad Sci U S A* **100**: 4269-4274.

Glaser ST, Kaczocha M and Deutsch D G (2005) Anandamide transport: a critical review. *Life Sci* **77**: 1584-1604.

Hermann A, Kaczocha M and Deutsch D G (2006) 2-arachidonoylglycerol (2-AG) membrane transport: history and outlook. *AAPS J* **8**: E409-E412.

Hillard CJ, Edgemond W S, Jarrahan A and Campbell W B (1997) Accumulation of N-arachidonylethanolamine (anandamide) into cerebellar granule cells occurs via facilitated diffusion. *J Neurochem* **69**: 631-638.

Hillard CJ and Jarrahan A (2000) The movement of N-arachidonylethanolamine (anandamide) across cellular membranes. *Chem Phys Lipids* **108**: 123-134.

Hillard CJ and Jarrahan A (2003) Cellular accumulation of anandamide: consensus and controversy. *BrJ Pharmacol* **140**: 802-808.

Hillard CJ, Shi L, Tuniki V R, Falck J R and Campbell W B (2007) Studies of anandamide accumulation inhibitors in cerebellar granule neurons: comparison to inhibition of fatty acid amide hydrolase. *J Mol Neurosci* **33**: 18-24.

Hohmann AG and Suplita R L (2006) Endocannabinoid mechanisms of pain modulation. *AAPS J* **8**: E693-E708.

Kaczocha M, Hermann A, Glaser S T, Bojesen I N and Deutsch D G (2006) Anandamide uptake is consistent with rate-limited diffusion and is regulated by

MOL #55251

the degree of its hydrolysis by fatty acid amide hydrolase. *J Biol Chem* **281**: 9066-9075.

Karlsson M, Contreras J A, Hellman U, Tornqvist H and Holm C (1997) cDNA cloning, tissue distribution, and identification of the catalytic triad of monoglyceride lipase: evolutionary relationship to esterases, lysophospholipases, and haloperoxidases. *J Biol Chem* **272**: 27218-27223.

Kirkham TC and Tucci S A (2006) Endocannabinoids in appetite control and the treatment of obesity. *CNS Neurol Disord Drug Targets* **5**: 272-292.

Kozak KR, Gupta R A, Moody J S, Ji C, Boeglin W E, DuBois R N, Brash A R and Marnett L J (2002) 15-Lipoxygenase metabolism of 2-arachidonylglycerol. generation of a peroxisome proliferator-activated receptor alpha agonist. *J Biol Chem* **277**: 23278-23286.

La Rana G, Russo R, D'Agostino G, Sasso O, Raso G M, Iacono A, Meli R, Piomelli D and Calignano A (2008) AM404, an anandamide transport inhibitor, reduces plasma extravasation in a model of neuropathic pain in rat: role for cannabinoid receptors. *Neuropharmacology* **54**: 521-529.

Lauckner JE, Jensen J B, Chen H Y, Lu H C, Hille B and Mackie K (2008) GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. *Proc Natl Acad Sci U S A* **105**: 2699-2704.

Ligresti A, Morera E, Van Der Stelt M, Monory K, Lutz B, Ortar G and Di Marzo V (2004) Further evidence for the existence of a specific process for the membrane transport of anandamide. *Biochem J* **380**: 265-272.

Long JZ, Li W, Booker L, Burston J J, Kinsey S G, Schlosburg J E, Pavon F J, Serrano A M, Selley D E, Parsons L H, Lichtman A H and Cravatt B F (2009) Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. *Nat Chem Biol* **5**: 37-44.

Maccarrone M, Bari M, Lorenzon T, Bisogno T, Di Marzo V and Finazzi-Agro A (2000) Anandamide uptake by human endothelial cells and its regulation by nitric oxide. *J Biol Chem* **275**: 13484-13492.

Maccarrone M, Bari M, Battista N and Finazzi-Agro A (2002) Estrogen stimulates arachidonylethanolamide release from human endothelial cells and platelet activation. *Blood* **100**: 4040-4048.

McFarland MJ and Barker E L (2004) Anandamide transport. *Pharmacol Ther* **104**: 117-135.

McFarland MJ, Bardell T K, Yates M L, Placzek E A and Barker E L (2008) RNA interference-mediated knockdown of dynamin 2 reduces endocannabinoid uptake into neuronal dCAD cells. *Mol Pharmacol* **74**: 101-108.

MOL #55251

McFarland MJ, Porter A C, Rakhshan F R, Rawat D S, Gibbs R A and Barker E L (2004) A role for caveolae/lipid rafts in the uptake and recycling of the endogenous cannabinoid anandamide. *J Biol Chem* **279**: 41991-41997.

McKinney MK and Cravatt B F (2005) Structure and function of fatty acid amide hydrolase. *Annu Rev Biochem* **74**: 411-432.

Minkkila A, Saario S M, Kasnanen H, Leppanen J, Poso A and Nevalainen T (2008) Discovery of boronic acids as novel and potent inhibitors of fatty acid amide hydrolase. *J Med Chem*.

Mitchell VA, Greenwood R, Jayamanne A and Vaughan C W (2007) Actions of the endocannabinoid transport inhibitor AM404 in neuropathic and inflammatory pain models. *Clin Exp Pharmacol Physiol* **34**: 1186-1190.

Moody JS, Kozak K R, Ji C and Marnett L J (2001) Selective oxygenation of the endocannabinoid 2-arachidonylglycerol by leukocyte-type 12-lipoxygenase. *Biochemistry* **40**: 861-866.

Moore SA, Nomikos G G, Dickason-Chesterfield A K, Schober D A, Schaus J M, Ying B P, Xu Y C, Phebus L, Simmons R M A, Li D, Iyengar S and Felder C C (2005) Identification of a high-affinity binding site involved in the transport of endocannabinoids. *Proc Natl Acad Sci U S A* **102**: 17852-17857.

Moriello AS, Balas L, Ligresti A, Cascio M G, Durand T, Morera E, Ortar G and Di Marzo V (2006) Development of the first potential covalent inhibitors of anandamide cellular uptake. *J Med Chem* **49**: 2320-2332.

Munro S, Thomas K L and Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. *Nature* **365**: 61-65.

O'Sullivan SE (2007) Cannabinoids Go Nuclear: Evidence for activation of peroxisome proliferator-activated receptors. *Br J Pharmacol* **152**: 576-582.

Ortar G, Schiano M A, Cascio M G, De Petrocellis L, Ligresti A, Morera E, Nalli M and Di M, V (2008) New tetrazole-based selective anandamide uptake inhibitors. *Bioorg Med Chem Lett* **18**: 2820-2824.

Ortega-Gutierrez S, Hawkins E G, Viso A, Lopez-Rodriguez M L and Cravatt B F (2004) Comparison of anandamide transport in FAAH wild-type and knockout neurons: evidence for contributions by both FAAH and the CB1 receptor to anandamide uptake. *Biochemistry* **43**: 8184-8190.

Pertwee RG (2002) Cannabinoids and multiple sclerosis. *Pharmacology Ther* **95**: 165-174.

MOL #55251

Rakhshan F, Day T A, Blakely R D and Barker E L (2000) Carrier-mediated uptake of the endogenous cannabinoid anandamide in RBL- 2H3 cells. *J Pharmacol Exp Ther* **292**: 960-967.

Ryberg E, Larsson N, Sjogren S, Hjorth S, Hermansson N O, Leonova J, Elebring T, Nilsson K, Drmota T and Greasley P J (2007) The orphan receptor GPR55 is a novel cannabinoid receptor. *Br J Pharmacol* **152**: 1092-1101.

Saario SM and Laitinen J T (2007) Monoglyceride lipase as an enzyme hydrolyzing 2-arachidonoylglycerol. *Chem Biodivers* **4**: 1903-1913.

Sang N, Zhang J and Chen C (2006) PGE2 glycerol ester, a COX-2 oxidative metabolite of 2-arachidonoyl glycerol, modulates inhibitory synaptic transmission in mouse hippocampal neurons. *J Physiol* **572**: 735-745.

Seierstad M and Breitenbucher J G (2008) Discovery and development of fatty acid amide hydrolase (FAAH) inhibitors. *J Med Chem*.

Shu-Jung Hu S, Bradshaw H B, Chen J S C, Tan B and Michael Walker J (2008) Prostaglandin E2 glycerol ester, an endogenous COX-2 metabolite of 2-arachidonoylglycerol, induces hyperalgesia and modulates NF-kappa B activity. *Br J Pharmacol* **153**: 1538-1549.

Smart D, Gunthorpe M J, Jerman J C, Nasir S, Gray J, Muir A I, Chambers J K, Randall A D and Davis J B (2000) The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (HVR1). *Br J Pharmacol* **129**: 227-230.

Trezza V and Vanderschuren L J (2009) Divergent effects of anandamide transporter inhibitors with different target selectivity on social play behavior in adolescent rats. *J Pharmacol Exp Ther* **328**: 343-350.

Veldhuis WB, van der S M, Wadman M W, van Zadelhoff G, Maccarrone M, Fezza F, Veldink G A, Vliegenthart J F, Bar P R, Nicolay K and Di M, V (2003) Neuroprotection by the endogenous cannabinoid anandamide and arvanil against *in vivo* excitotoxicity in the rat: role of vanilloid receptors and lipoxygenases. *J Neurosci* **23**: 4127-4133.

Wang H, Dey S K and Maccarrone M (2006) Jekyll and Hyde: two faces of cannabinoid signaling in male and female fertility. *Endocr Rev* **27**: 427-448.

Wei BQ, Mikkelsen T S, McKinney M K, Lander E S and Cravatt B F (2006) A second fatty acid amide hydrolase with variable distribution among placental mammals. *J Biol Chem* **281**: 36569-36578.

Witkin JM, Tzavara E T and Nomikos G G (2005) A role for cannabinoid CB1 receptors in mood and anxiety disorders. *Behav Pharmacol* **16**: 315-331.

MOL #55251

Woodward DF, Carling R W, Cornell C L, Fliri H G, Martos J L, Pettit S N, Liang Y and Wang J W (2008) The pharmacology and therapeutic relevance of endocannabinoid derived cyclo-oxygenase (COX)-2 products. *Pharmacol Ther* **120**: 71-80.

Yang H, Zhang J, Andreasson K and Chen C (2008) COX-2 oxidative metabolism of endocannabinoids augments hippocampal synaptic plasticity. *Mol Cell Neurosci* **37**: 682-695.

Zygmunt PM, Petersson J, Andersson D A, Chuang H h, Sorgard M, Di Marzo V, Julius D and Hogestatt E D (1999) Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. *Nature* **400**: 452-457.

MOL #55251

Legends for Figures





Figure 1. Various proposed models for endocannabinoid transport. Although the majority of these models were developed based on data from AEA uptake studies, there is some evidence to suggest that AEA and 2-AG uptake occur via a common mechanism. *A)* A transmembrane carrier protein assists in the translocation of endocannabinoids across the plasma membrane; *B)* Endocannabinoids passively diffuse across the plasma membrane along a catabolism-driven concentration gradient, but are sequestered in an intracellular compartment or by binding to an intracellular binding protein prior to metabolism; *C)* Endocannabinoids passively diffuse across the plasma membrane along a concentration gradient that is driven by their rapid metabolism; *D)* Endocannabinoids are transported into cells via a protein carrier-mediated caveolae-related endocytic event.

Figure 2. Hydrolysis of the endocannabinoids AEA and 2-AG. *A)* FAAH catalyzes the hydrolysis of AEA into arachidonic acid and ethanolamine. *B)* MAGL catalyzes the hydrolysis of 2-AG into arachidonic acid and glycerol.


Figure 3. The major metabolites generated via COX-2-mediated oxidation of the endocannabinoids *A)* AEA and *B)* 2-AG. Prostaglandin E2 ethanolamide, PGE₂-EA; prostaglandin E2 glycerol ester, PGE₂-GE.

MOL #55251


Figure 4. The major metabolites generated via oxidation of *A*) AEA and *B*) 2-AG by the 12- and 15-LOXs. Hydroperoxyeicosatetraenoylethanolamide, HETE-EA; hydroperoxyeicosatetraenoic acid glycerol ester, HETE-GE.




A




B




A



B



A



B

